HCV Screening, Management, and Treatment Guidelines
|
|
- Milton Baldric Fox
- 5 years ago
- Views:
Transcription
1 HCV ECHO WESTERN STATES HCV Screening, Management, and Treatment Guidelines Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health Sciences Center Brad Moran, PharmD Chief of Pharmacy Fort Peck Service Unit IHS October 5, 2018 Original presentation by: Date prepared:
2 Agenda 1. Recognize and stage a patient s level of liver disease using common laboratory tests and imaging 2. Describe new therapeutic options for the treatment of chronic HCV 3. Recognize and assess the clinical significance of common drug-drug interactions with oral-hcv therapies 4. Use national algorithms and guidelines to guide treatment strategies for patients with HCV infection
3 HCV ECHO WESTERN STATES Conflict of Interest Disclosure Statement
4 Hepatitis Spread via blood-to-blood contact usually asymptomatic Leading cause for liver transplantation in the US ~75-80% of acute infections become chronic chronic infection- detection of virus 6 months post-exposure No vaccine available Prevalence is 1.6% of US population
5 Hepatitis C is a Global Health Problem Estimated 170 million persons with HCV infection worldwide > 10% 2.5%-10% 1%-2.50% Prevalence of infection NA World Health Organization 2008 (
6 Risk Factors for HCV Infection Persons born between Received blood transfusion or organ donation prior to 1992 Current or former injection drug users Chronic hemodialysis patients Any known blood exposure to HCV-positive blood Persons with HIV Children born to HCV-infected mother
7 CDC Testing Algorithm for Chronic HCV
8 Hepatitis C Genotypes 15% Prevalence in US population 7% 4% Genotype 1 6 major genotypes (1-6), most with subtypes Genotype 1 - GT 1b different than GT 1a 74% Genotype 2 Genotype 3 Genotypes 4-6 GT 2 easier to treat than GT 3 GT 3 associated with higher mortality, steatohepatitis Alter MJ et al. N Engl J Med 1999; 341:556-62
9 Hepatitis C Epidemiology-Fort Peck Reservation HCV AB TESTS PERFORMED *2018
10 FPSU HCV Epidemiology HCV Ab+ Chronic HCV Spontaneous clearance number of living patients *no confirmatory
11 Age Group HCV Ab+ by age group and younger # patients
12 Natural history following initial infection with HCV Time years years
13 HCV is Not Just a Liver Disease Common Symptoms of HCV in Absence of Cirrhosis Fatigue Impaired cognitive function (brain fog) Migratory arthralgia or myalgia Depression Extrahepatic Manifestations of Chronic HCV Renal Disease Lymphomas Neuropathy Dermatologic Manifestations Diabetes Neurological Impairments
14 Overview: Routine Evaluation and Follow Up of Persons with Chronic HCV Baseline studies Screening for other causes of liver disease Vaccinations Staging of Liver Disease Special considerations for cirrhotic patients: Monitoring for hepatocellular carcinoma Evaluation for cirrhosis related complications Referral for liver transplantation Assessment and management of alcohol and substance abuse
15 Overview: Part 2- HCV Therapy HCV Therapies Special populations Choosing a regimen Common side effects and laboratory abnormalities Drug-drug interactions Monitoring of patients on HCV therapy Monitoring of patients after HCV therapy
16 Baseline Studies in Persons with Chronic HCV Complete blood count with differential Comprehensive metabolic panel including serum creatinine Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total and direct bilirubin, serum albumin International normalized ratio (INR) HCV genotype and subtype Quantitative HCV RNA HIV antibody Hepatitis A serology (IgG or total) Hepatitis B serology (HBsAg, anti- HBs, anti-hbc) Alpha-fetal protein (AFP) Abdominal ultrasound with measurement of spleen size
17 Baseline Studies in Persons with Chronic HCV Complete blood count with differential Comprehensive metabolic panel including serum creatinine Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total and direct bilirubin, serum albumin Identify changes consistent with cirrhosis; identify anemia especially if requiring ribavirin therapy Evaluate renal function for choosing appropriate HCV therapy Recognize level of inflammation and liver injury International normalized ratio (INR) Assess hepatic synthetic function
18 Why is the CBC Important to Understand Liver Disease Severity? Thrombocytopenia (<150 thousand) Due to portal hypertension caused by cirrhosis Portal hypertension causes: Platelets to become stuck in spleen More platelets damaged/destroyed Neutropenia Cirrhosis can cause bone marrow suppression
19 Abnormalities in Hepatic Panel Elevations in AST or ALT useful for measuring liver cell injury What is normal AST or ALT? 40 IU/mL Studies suggest this is too high and normal should be lower and different for men vs. women Healthy ALT is <30 IU/mL for men and <19 IU/mL for women Elevations in conjugated bilirubin suggest liver disease Loss of liver s ability to synthesize (lack of synthetic function) can be seen with: Low serum albumin Prolonged prothrombin time (elevated INR) Important to look at trends in labs over time
20 Baseline Studies in Persons with Chronic HCV HCV genotype and subtype Quantitative HCV RNA Determine appropriate HCV therapy and treatment duration; demonstrate chronic HCV HIV antibody Hepatitis A serology (IgG or total) Hepatitis B serology (HBsAg, anti- HBs, anti-hbc) Share similar routes of transmission; determine need for HAV and/or HBV vaccination; determine risk for HBV reactivation Alpha-fetal protein (AFP) Abdominal ultrasound with measurement of spleen size Evaluate for cirrhosis; screen for hepatocellular carcinoma
21 Other Viral Hepatitis Hepatitis A Check HAV antibody (total or IgG) Hepatitis B Check hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-hbs; total or IgG), and hepatitis B core antibody (anti-hbc) Labs needed irrespective of vaccination
22 Hepatitis B Serologies Test Result Interpretation HBsAg Anti-HBc Anti-HBs HBsAg Anti-HBc Anti-HBs Negative Negative Negative Negative Positive Positive or Negative Susceptible to HBV Previous exposure to HBV.These patients are not immune or protected and frequently have subclinical infection and are at risk for reactivation with immunosuppression. There is no role to vaccinate (or boost) these patients. HBsAg Anti-HBc Anti-HBs HBsAg Anti-HBc IgM anti-hbc Anti-HBs HBsAg Anti-HBc IgM anti-hbc Anti-HBs Negative Negative Positive Positive Positive Positive Negative Positive Positive Negative Negative Immune to HBV due to HBV vaccine Acute HBV infection Chronic HBV infection
23 HBV Reactivation Risk in HCV FDA warning issued 2016 following 24 reported cases of HBV reactivation in patients treated with HCV DAAs 2 deaths 1 liver transplant Mechanism of reactivation unclear HCV DAAs do not have immunosuppressive effects Current recommendations are to evaluate patients for potential coinfection of HCV and HBV
24
25 Vaccinations HAV HBV Pneumococcal vaccine for all patients with chronic liver disease, including on-going alcoholism Annual flu
26 Disease States Potentiating Fibrosis NASH NAFLD Alcohol Fibrosis Viral Hepatitis HIV Autoimmune Practice guidelines:
27 Natural history following initial infection with HCV Time years years
28 Findings Suggestive of Advanced Fibrosis/ Cirrhosis Presence or history of ascites or esophageal varices Low platelet count (<150,000 mm 3 ) APRI > 1.0 FIB-4 > 3.25 Fibrosure > 0.72 Imaging with evidence of cirrhosis (nodular contour of liver or evidence of portal hypertension) Liver biopsy with F3 or F4 fibrosis Transient elastography consistent with advanced fibrosis/cirrhosis
29 Use an upper limit of normal of 40
30
31 Child-Pugh Classification of Cirrhosis for Drug Dosing 1 Point 2 Points 3 Points Encephalopathy None Moderate Severe Ascites Absent Mild- Moderate Severe/ Refractory Bilirubin (mg/dl) < > 3 Albumin (g/dl) > < 2.8 INR (PT Prolongation sec over control) <1.7 (0-4) >2.3 (>6)
32 Child-Pugh Interpretation of Hepatic Function in a Patient with Cirrhosis C-P Score (Class) Liver Function 5-6 (A) Mild Dysfunction 7-9 (B) > 9 (C) Moderate Dysfunction Moderate dose reduction (~25%) for drugs that are mostly hepatically metabolized Severe Dysfunction Significant dose reduction (~50%) for drugs that are mostly hepatically metabolized Note: Child Pugh Score is calculated only for patients with cirrhosis
33 Liver Biopsy is Gold Standard but Liver biopsy is not reliable gold standard Sampling error leads to misinterpretation in 10-15% of cases Can miss the diagnosis of cirrhosis Invasive procedure with complications Expensive Poor patient acceptance Interpretation has significant inter observer variability Seeff LB, et al. Clin Gastroenterol Hepatol. 2010;8: The French METAVIR Cooperative Study Group. Hepatology. 1994;20:15-20
34 Hepatocellular Carcinoma Incidence of HCC is estimated at 2-8% per year in patients with chronic HCV and advanced fibrosis/cirrhosis All patients with cirrhosis should be screened for HCC and continue with HCC surveillance every 6 months (indefinitely) Abdominal ultrasound plus AFP Biomarkers MRI or CT for suspicious lesions or concerns for HCC
35 Natural History of Chronic Liver Disease Chronic liver disease Compensated cirrhosis Decompensated cirrhosis Death Development of complications: Variceal hemorrhage Ascites Encephalopathy Jaundice
36 Evaluating Patients with Cirrhosis: Related Complications Physical exam for edema, muscle wasting, encephalopathy, and/or ascites Endoscopy for presence of esophageal varices and need for esophageal banding/prophylaxis Additional info at AASLD guidelines:
37 Probability of Survival Patients with Cirrhosis Decompensation Shortens Survival All patients with cirrhosis Median survival~ 9 years 20 Decompensated cirrhosis Median survival~ 1.6 years Months Source: Ginés P, et al. Hepatology 1987; 7:122-8.
38 Indications for Referral to Hepatologist and for Liver Transplantation Periodic assessment of cirrhotic patients using a validated prognostic tool such as MELD score (Model for End-Stage Liver Disease) can predict mortality and is used as indicator for liver transplantation Patients with a score of 15 or higher should be considered for evaluation of liver transplant
39 MELD Calculator and Interpretation
40 Alcohol and On-going Substance Abuse No indications to withhold HCV therapy based on active alcohol or substance use Tobacco- can increase risk of HCC Marijuana- daily use associated with increased fibrosis Alcohol- hepatotoxic
41 Disease States Potentiating Fibrosis NASH NAFLD Fibrosis Alcohol Patient should be counseled on maintaining a healthy diet and normal BMI (<25 kg/m 2 ) Viral Hepatitis HIV Autoimmune
42 Mental health assessment Patients with HCV have higher rates of depression Underlying depression can affect medication adherence
43 When Will There Be Good News? Coffee and tea may be liver protective Statins may be hepatoprotective and may decrease the risk of HCC Jaruvongvanich V., et al Clin Res Hepatol Gastroenterol.
44 Summary: Pre-Treatment Laboratories (within 60 days of start of treatment) CBC with differential Chem 7 Liver enzymes: ALT, AST, alkaline phosphatase Liver function tests: albumin, total and direct bilirubin, INR Vitamin D 25-OH Urine or serum pregnancy test for women of childbearing capacity (ribavirin only) Alpha fetoprotein (if cirrhosis) HIVRNA and CD4 count (if HIV infected) The following labs should be current within the past 12 months*: HCV-RNA Quant Patients must have documentation of the following labs: HCV GT and subtype HBsAg, anti-hbs, anti-hbc (irrespective of vaccine history) HAV Ab (unless documentation of vaccination) HIV Ab *For non-cirrhotic, treatment naïve patients with genotype 1, an HCV-RNA within 6 months of starting therapy must be available for consideration of an 8 week course of treatment.
45 Pre-Treatment Resistance Testing VERY LIMITED Prior to using sofosbuvir/velpatasvir in patients with HCV GT3 who have cirrhosis and/or are treatment experienced RAS testing for HCV GT3- looking for Y93 mutation All patients with HCV GT1a when considering use of elbasvir/grazoprevir require pre-treatment resistance testing for NS5A resistance associated substitutions (RASs)
46 Changes in HCV Therapy
47 Goals of HCV Therapy Cure Defined as sustained virologic response (SVR) Improvements in liver function Improvements in fibrosis, reversal of cirrhosis? Prevent decompensation Improvements in extrahepatic manifestations of HCV Prevent deaths due to liver disease complications Prevent liver cancer Reduce rates of liver cancer recurrence
48 Differences in Therapy Interferon Based Injectable Long duration of treatment High side effect profile Multiple laboratory abnormalities Low cure rates Direct Acting Antivirals Oral Short durations Minimal side effects Minimal laboratory abnormalities High cure rates
49 Treatment Terminology Treatment naïve (TN): no prior HCV therapy Treatment experienced (TE): prior HCV therapy- important to clarify which prior treatment Interferon Direct acting antivirals only Sustained virologic response (SVR): cure, defined as undetectable HCV RNA at least 12 weeks after end of treatment (EOT) Durable Relapser: patient who achieves an undetectable HCV RNA on treatment but has a detectable HCV RNA after treatment is completed
50 The Evolution of Highly Effective Treatment IFN 6 mos PegIFN RBV 12 mos IFN 12 mos IFN/ RBV 12 mos Standard IFN RBV PegIFN 1991 BOC and TPV PegIFN/ RBV/ BOC or TPV 6-12 mos IFN/ RBV 6 mos SOF 89+ SMV 80+ PegIFN/ RBV/ SMV wks PegIFN/ RBV/ SOF wks 2014 LDV/ SOF >90 >90 PrOD LDV/ SOF 8-12 wks PrOD + RBV wks EBR/ GZR wks SOF + DCV 12 wks DCV+ SOF EBR/ GZR 2016 >90 >90 SOF/ VEL >90 SOF/ VEL 12 wks SOF/ VEL/ VOX 2017 GLE/ PIB >90 >90 GLE/ PIB 8-12 wks SOF/ VEL/ VOX 12 wks
51 HCV Direct Acting Antivirals (DAAs) Target NS3/4A: Protease Inhibitors (-previr) NS5A: Replication Complex Inhibitors (-asvir) NS5B: Polymerase Inhibitors (-buvir) Pulled from market Boceprevir Telaprevir Simeprevir Paritaprevir Grazoprevir Glecaprevir Voxilaprevir Ledipasvir Ombitasvir Daclatasvir Elbasvir Velpatavir Pibrentasvir Nucleotide: Sofosbuvir Non-nucleoside: Dasabuvir
52 HCV Direct Acting Antivirals (DAAs) Generic Name Elbasvir/ Grazoprevir Glecaprevir/Pibrentasvir Ledipasvir/Sofosbuvir Paritaprevir/ritonavir/Ombitasvir Paritaprevir/ritonavir/Ombitasvir with Dasabuvir Sofosbuvir/ Velpatasvir Sofosbuvir/ Velpatasvir/Voxilaprevir Brand Name Zepatier Mavyret Harvoni Technivie Viekira Pak Epclusa Vosevi Other Therapies Ribavirin Single Agent Therapies Daclatasvir Sofosbuvir Ribasphere, RibaPak, Copegus, Rebetol Daklinza Sovaldi
53 What Predicts Treatment Success or Failure? Patients who are treatment naïve and non-cirrhotic have very high SVR rates Underlying cirrhosis can decrease SVR Medication adherence
54 Overview of HCV Therapies
55 Joint guidelines of the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) Updated frequently- check online for most current version of guidelines Available at:
56 Ledipasvir/Sofosbuvir Combination of NS5B polymerase inhibitor (Sofosbuvir); NS5A inhibitor (ledipasvir) Administration One tablet once daily with food or without food Requires acidic environment for absorption Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc.; Indicated for GT 1 and 4 for 12 weeks
57 Who Can Be Treated with Ledipasvir/Sofosbuvir? Patients without cirrhosis Patients with cirrhosis, including Child s class A, B or C cirrhosis Restricted to patients with glomerular filtration rates greater than 30 ml/min/1.73 m 2 Approved for use in children 12 yo and older or 35 kg and above
58 SVR12 (%) ION Phase 3 Program (ION-1, ION-2, ION-3) Efficacy Summary LDV/SOF LDV/SOF+RBV / / / / Weeks 24 Weeks 8 Weeks 12 Weeks 12 Weeks 24 Weeks ION-1 GT 1 treatment-naïve including cirrhotics 202/ / / 216 ION-3 GT 1 treatment-naïve non-cirrhotic 102/ / / / 111 ION-2 GT 1 treatment-experienced including cirrhotics and PI failures 97% (1886/1952) overall SVR rate Error bars represent 95% confidence intervals. Afdhal N, et al. N Engl J Med 2014; 2014 Apr 12 [Epub ahead of print] Kowdley K, et al. N Engl J Med 2014; 2014 Apr 11 [Epub ahead of print] Afdhal N, et al. N Engl J Med 2014; 2014 Apr 12 [Epub ahead of print]
59 Sofosbuvir/Velpatasvir Fixed-dose combination of sofosbuvir (NS5B inhibitor) and velpatasvir (NS5A inhibitor) Approved for chronic HCV genotypes 1, 2, 3, 4, 5, or 6 for 12 week duration of therapy Epclusa [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2016.
60 Who Can Be Treated with SOF/VEL? Patients without cirrhosis Patients with cirrhosis, including Child s class A, B or C cirrhosis Restricted to patients with glomerular filtration rates greater than 30 ml/min/1.73 m 2
61 SVR12 (%) ASTRAL-1: SOF/VEL STR for 12 Weeks in GT 1, 2, 4, 5, 6 HCV-Infected Patients SVR12 by Cirrhosis Status or Treatment History / / / /423 Total Non-Cirrhotic Cirrhotic Treatment- Naïve 200/201 Treatment- Experienced Error bars represent 95% confidence intervals. Feld, AASLD, 2015, LB-2. Feld JJ, et al. N Engl J Med DOI: /NEJMoa
62 Glecaprevir/Pibrentasvir Combination of Glecaprevir an NS3/4A protease inhibitor Pibrentasvir an NS5A inhibitor Dosage and administration: 3 tablets once daily with food Indicated for 8 weeks in patients without cirrhosis; 12 weeks if cirrhotic
63 Patients (%) with SVR 12 Glecaprevir-Pibrentasvir for 8 or 12 weeks in Non-Cirrhotic GT 1 ENDURANCE-1: Baseline Characteristics GLE-PIB x 8 Weeks GLE-PIB x 12 Weeks / / / /332 ITT-PS ITT-PS-PP ITT-PS population: ITT excluding patients with HIV coinfection or treatment experience with sofosbuvir ITT-PS-per protocol (PP) population: ITT-PS excluding patients with premature discontinuation of study drug, virologic failure before Week 8, and missing SVR12 data Source: Zeuzem S, et al. AASLD 2016.Abstract 253.
64 Patients with SVR 12 (%) Glecaprevir-Pibrentasvir in Treatment-Naïve Non-Cirrhotic GT 3 ENDURANCE-3 Study: Results ION-3: SVR 12 by Treatment Duration and Regimen (ITT Analysis) / / /157 GLE-PIB SOF + DCV GLE-PIB 12-Week Regimens 8-Week Regimen GLE-PIB = glecaprevir-pibrentasvir; SOF = sofosbuvir; DCV = daclatasvir ITT = Intent-to-treat Source: Foster G, et al. EASL Abstract GS-007.
65 Patients with SVR12 (%) Glecaprevir-Pibrentasvir in Genotype 1-6 with Renal Disease EXPEDITION-4: Results SVR12 by Type of Analysis discontinuation 1 lost to follow-up / /102 ITT mitt ITT, intent-to-treat analysis; mitt, modified intent-to-treat analysis Source: Gane E, et. al, AASLD Abstract 935.
66 Sofosbuvir/Velpatasvir/Voxilaprevir Vosevi [package insert]. Foster City, CA: Gilead Sciences, Inc.; Combination of NS5B polymerase inhibitor (Sofosbuvir); NS5A inhibitor (Velapatasvir); NS3/4A protease inhibitor (Voxilaprevir) Administration One tablet once daily with food Indicated for patients who previously failed DAA therapy
67 Who Can Be Treated with SOF/VEL/VOX? Patients without cirrhosis Patients with Child s class A cirrhosis (compensated cirrhosis) Not recommended in patients with Child s Class B or C cirrhosis Restricted to patients with glomerular filtration rates greater than 30 ml/min/1.73 m 2
68 SVR12, % POLARIS-1: SOF/VEL/VOX for 12 Weeks in NS5A Inhibitor-Experienced HCV GT 1 6 SVR12 Results Overall and by Cirrhosis Status relapses 1 on-treatment failure** 2 withdrew consent 1 LTFU 1 withdrew consent 1 LTFU 6 relapses 1 on-treatment failure** 1 withdrew consent / / /121 Overall* No Cirrhosis Cirrhosis * p <0.001 for superiority compared with prespecified 85% performance goal for SOF/VEL/VOX ** Exposure was consistent with non-adherence Bourliere M, AASLD 2016, Oral 194
69 SVR12, % POLARIS-1: SOF/VEL/VOX for 12 Weeks in NS5A Inhibitor-Experienced HCV GT 1 6 SVR12 by Genotype and Cirrhosis Status No Cirrhosis Cirrhosis * Overall GT 1 GT 1a GT 1b GT 2 GT 3 GT 4/5/ *1/1 patient with GT unknown achieved SVR12; 4/4 patients with GT 1 other (cirrhosis, n=2; no cirrhosis, n=2) achieved SVR12; Includes only GT 4 patients. Data on file, Gilead Sciences 72
70 SVR12, % POLARIS-4: SOF/VEL/VOX or SOF/VEL for 12 Weeks in Non-NS5A Inhibitor DAA- Experienced HCV GT 1 4 SVR12 by Genotype and Cirrhosis Status No Cirrhosis Cirrhosis SOF/VEL/VOX 12 Weeks Overall SVR12 97% SOF/VEL 12 Weeks Overall SVR12 90% GT 1a GT 1b GT 2 GT 3 GT GT 1a GT 1b GT 2 GT 3 GT Data on file, Gilead Sciences 73
71 Ribavirin Still utilized in combination with other HCV therapies in more difficult to treat patient populations and/or when specific RAS concerns exist Well-known to cause toxicity profile Hemolytic anemia Occurs within 1-2 weeks and peaks after 4-6 weeks Can see increase in indirect bilirubin Teratogenic Pregnancy category X
72 Side Effect Profile of DAAs Overall very well tolerated Most commonly reported side effects: Headache Fatigue Nausea Diarrhea (reported with voxilaprevir)
73 Laboratory Abnormalities with DAAs Overall not common Most common laboratory abnormalities: ALT elevations Concomitant use of ethinyl-estradiol with glecaprevir/pibrentasvir Bilirubin elevations Many DAAs inhibit bilirubin transporters Anemia with concomitant use of ribavirin Ribavirin causes hemolytic anemia
74 Rapid Viral Decline
75 Rapid Improvements in Inflammation
76 Ribavirin Induced Hemolytic Anemia
77 What About Medications in Patients with HCV? In patients undergoing HCV therapy Avoid herbals Verify potential drug interactions using Liverpool website In patients with cirrhosis Avoid NSAIDs Acetaminophen preferred for short-term pain management at <2 grams per day
78 Other Main Drug Interaction Concerns for DAAs Statins: Interactions vary by DAA and statin Acid suppressive therapy: Ledipasvir and velpatasvir require acidity for absorption greatest concern with velpatasvir Avoid amiodarone Amiodarone with sofosbuvir and other DAA: Serious symptomatic bradycardia
79 Major Drug-Drug Interactions for all Direct Acting Antivirals Carbamazepine Oxcarbazepine Phenytoin Phenobarbital Rifampin Expected to concentrations DO NOT USE WITH HCV THERAPY!
80 Also available as an app: hepichart
81 Use of HCV Therapies in Special Populations
82 Use of HCV DAAs in Renal Insufficiency and Cirrhosis Ledipasvir/ sofosbuvir Elbasvir/gra zoprevir Sofosbuvir/ velpatasvir Sofosbuvir/ velpatasvir/ voxilaprevir Glecaprevir/ pibrentasvir Use in renal impairment or endstage renal disease? > 30 ml/min Safe to use in all levels of renal impairment including dialysis > 30 ml/min > 30 ml/min Safe to use in all levels of renal impairment including dialysis Use in cirrhosis? Childs Class A, B or C Child Class A Childs Class A, B or C Child Class A Child Class A
83
84
85
86
87
88
89 Treatment Flowsheet Example
90 Treatment Flowsheet Example: With Ribavirin
91 Resources AASLD/IDSA HCV Treatment Guidelines: Available at: HCV Drug Interactions (University of Liverpool): Available at: Educational material, clinical calculators, HCV therapy summaries (University of Washington) Available at:
92 HCV ECHO WESTERN STATES End of Presentation Questions?
93 POOR CORRELATION OF AMMONIA LEVELS WITH PRESENCE OR SEVERITY OF HEPATIC ENCEPHALOPATHY Poor Correlation of Ammonia Levels With Presence or Severity of Encephalopathy Venous total ammoni a mmol/l Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Severity of Hepatic Encephalopathy Ong et al., Am J Med 2003; 114:188
94 Can Active Drug Users Adhere to HCV Therapy and Achieve Cure? Immediate Treatment Group Deferred Treatment Group Mean Drug Adherence (%) SVR12, n/m (%) Mean Drug Adherence (%) SVR12, n/m (%) All patients /201 (91.5) /95 (89.5) Patients with positive UDS at Day 1 Opioids /44 (84.1) /19 (84.2) Amphetamine /10 (90) /6 (83.3) Cocaine /20 (95) /10 (80) Benzodiazepin es /51 (90.2) /26 (88.5) Cannabinoids /60 (93.3) /27 (99.6) n= number of all randomized patients achieving SVR12; m= number of all randomized patients with positive UDS for the indicated drug at day 1 Dore et al. Ann Intern Med. 2016;165:
HCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationHCV Screening, Management and Guidelines
HCV ECHO WESTERN STATES HCV Screening, Management and Guidelines Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health Sciences Center
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions
New York State HCV Provider Webinar Series Side Effects of Therapy and Drug-Drug Interactions Case Presentation Case 56 year-old lady with Genotype 1A Hepatitis C, Treatment-naive Noninvasive fibrosis
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description
More informationDescription of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases
Description of Antivirals for Hepatitis C LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Dwayne-David@cherokee.org Objectives Compare the different classes of direct-acting antiviral
More informationAnnual Hepatitis C Update
Annual Hepatitis C Update Target Audience: Pharmacists ACPE#: 0202-0000-18-064-L01-P Activity Type: Knowledge-based Target Audience: ACPE#: Activity Type: This activity is supported by an independent educational
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions
New York State HCV Provider Webinar Series Side Effects of Therapy and Drug-Drug Interactions Case Presentation Case 56 year-old lady with Genotype 1A Hepatitis C, Treatment-naive Noninvasive fibrosis
More informationManagement of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationRATIONALE FOR INCLUSION IN PA PROGRAM
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with
More informationHepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18
Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis
More informationSovaldi (sofosbuvir)
Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationHepatits C Criteria Direct Acting Antiviral Medications
Hepatits C Criteria Direct Acting Antiviral Medications Harvoni-Formulary PA required 1. Is the patient being treated for a funded condition by the Oregon Health Plan? 2. Does the member have a diagnosis
More informationCurrent HCV Treatment by Genotype
Current HCV Treatment by Genotype Ari Bunim, MD Assistant Professor Clinical Medicine Weill Cornell Medical College Clinical Director of Hepatology New York-Presbyterian/Queens Objectives To understand
More informationPrimary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 32 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 30 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationHepatitis C Update: Screening, Diagnosis, and Treatment
Mountain West AIDS Education and Training Center Hepatitis C Update: Screening, Diagnosis, and Treatment Brian R. Wood, MD (bwood2@uw.edu) Assistant Professor of Medicine, University of Washington Medical
More informationCases: Initial Treatment of Hepatitis C
Cases: Initial Treatment of Hepatitis C Kristen Marks, MD Assistant Professor of Medicine Weill Cornell Medical College New York, New York Off-Label Warning I will discuss the following off-label use in
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationHarvoni (sofosbuvir/ledipasvir
Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationHepatitis C: The New World of Treatment
Hepatitis C: The New World of Treatment Aban 1395, NIOC Hospital Shahin Merat, M.D. Professor of Medicine Digestive Disease Research Institute Tehran University of Medical Sciences 1 Drugs NS5B polymerase
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other DACLATASVIR DAKLINZA 41377 ELBASVIR/GRAZOPREVIR ZEPATIER 43030 GLECAPREVIR/PIBRENTASVIR MAVYRET 44453 OMBITASVIR/PARITAPREVIR/ RITONAVIR
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Harvoni) Reference Number: CP.CPA.175 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationHepatitis C: the 2015 Perspective for the Family Medicine Practitioner
Hepatitis C: the 2015 Perspective for the Family Medicine Practitioner Annie Luetkemeyer, MD Division of HIV,ID & Global Medicine San Francisco General Hospital Disclosures I have received research grant
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationManaging New Treatments for Hepatitis C in Primary Care
Managing New Treatments for Hepatitis C in Primary Care Christina Connel, PharmD, BCPS, AAHIVP Objectives 2 Review HCV disease burden Identify risk factors and recommended testing for HCV Describe who
More informationREQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments
Fax completed form to: 866-940-7328 Prior Authorization Phone Number: 800-310-6826 IA Medicaid Member ID # Patient name Date of Birth Patient address Patient phone Provider NPI Prescriber name Phone Prescriber
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: ERX.SPA.131 Effective Date:
Clinical Policy: (Daklinza) Reference Number: ERX.SPA.131 Effective Date: 10.01.16 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
DIRECT ACTING ANTIVIRAL AGENTS FOR HEPATITIS C VIRUS (HCV): DAKLINZA (daclatasvir) oral tablet EPCLUSA (velpatasvir, sofosbuvir) oral tablet HARVONI (ledipasvir, sofosbuvir) oral tablet MAVYRET (glecaprevir,
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationINFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL
Ohio Department of Medicaid Prior Authorization Form Unified PDL HEPATITIS C TREATMENT Member ID# Patient Name: DOB: Patient Address: Provider DEA: Provider NPI: Provider Name: Phone: Provider Address:
More informationOutline. HCV Disease Outcomes in the US. Hepatitis C: The New Landscape 5/24/16. Advances in Internal Medicine May 24, I have no disclosures
5/24/16 Hepatitis C: The New Landscape Advances in Internal Medicine May 24, 2016 I have no disclosures Rena K. Fo, MD Professor of Clinical Medicine, UCSF Outline I. Current HCV outcomes in the US II.
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationHepatitis C ew Medications, New Hope and New. V. Opportunities for Primary Care. Outline. HCV Disease Outcomes in the US 9/21/2016
Hepatitis C ew Medications, New Hope and New Opportunities for Primary Care Primary Care Principles and Practice October 14, 2016 Disclosures: Grant support Gilead Sciences, Inc Quality improvement Systematized
More informationUpdate on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017
Update on Hepatitis C Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 The global prevalence of HCV was 1 0% (95% uncertainty interval 0 8 1 1) in 2015: 71 1 million (62 5 79
More informationUpdates in the Treatment of HCV
Updates in the Treatment of HCV Misty Miller, Pharm.D., BCPS, AAHIVP Associate Professor University of Oklahoma College of Pharmacy September 21 st, 2018 Overview HCV Review and Definitions HCV Genotypes
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationKristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York
Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Learning Objectives After attending this presentation,
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationHepatitis C Prior Authorization Policy
Hepatitis C Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: December 2, 2016 Harvoni Description Harvoni (ledipasvir
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Epclusa) Reference Number: CP.CPA.286 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: March 18, 2016 Harvoni Description Harvoni (ledipasvir
More informationTHE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE
THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF
More informationArvind R. Murali, MD Assistant Professor of Medicine Gastroenterology & Hepatology Organ Transplant Center UIHC, Carver College of Medicine
Arvind R. Murali, MD Assistant Professor of Medicine Gastroenterology & Hepatology Organ Transplant Center UIHC, Carver College of Medicine No financial disclosures No conflicts of interest No affiliations
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: CP.CPA.283 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Daklinza) Reference Number: CP.CPA.283 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationCurrent HCV Treatment by Genotype Ira M. Jacobson, MD
Current HCV Treatment by Genotype Ira M. Jacobson, MD Director of Hepatology NYU School of Medicine Objectives To understand the prevalence of HCV and distribution of HCV genotypes Describe the HCV lifecycle
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationState of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT
State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationClinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17
Clinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17 Last Review Date: 9/17 Revision Log See Important Reminder at the end of
More informationHepatitis C Update: A Growing Challenge With Evolving Management Solutions
Pts (%) Hepatitis C Update: A Growing Challenge With Evolving Management Solutions A Growing Challenge With Evolving Management Solutions Introduction Magda Houlberg, MD Chief Clinical Officer Howard Brown
More informationClinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: HIM.PA.SP36 Effective Date: Last Review Date: 06.18
Clinical Policy: (Mavyret) Reference Number: HIM.PA.SP36 Effective Date: 08.01.17 Last Review Date: 06.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.32 Subject: Harvoni Page: 1 of 7 Last Review Date: December 3, 2015 Harvoni Description Harvoni (ledipasvir
More informationOn Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018
On Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018 Trana Hussaini, PharmD Pharmacotherapy Specialist in Liver Transplantation, VGH Clinical Assistant Professor, Faculty of Pharmaceutical
More informationClinical guidelines for the treatment of hepatitis C in Iceland
F the Treatment as Prevention f Hepatitis C in Iceland (TraP Hep C) A nationwide campaign f reducing disease burden using combination antiviral treatment Whom to treat All patients infected with the hepatitis
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationOptimizing HCV Treatment Continuity and Outcomes
Optimizing HCV Treatment Continuity and Outcomes Empowering Pharmacists to Take Action Faculty Michelle T. Martin, PharmD, BCPS, BCACP Clinical Pharmacist University of Illinois Hospital and Health Sciences
More informationPatients with compensated cirrhosis: how to treat and follow-up
Patients with compensated cirrhosis: how to treat and follow-up Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Universitätsklinikum Leipzig Leber- und Studienzentrum
More informationSOFOSBUVIR/VELPATASVIR Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR
Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR EPCLUSA 43561 GUIDELINES FOR USE 1. Is the patient at least 18 years old? If yes, continue to #2. 2. Does the patient have a diagnosis of
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationGlecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
Phase 3 Treatment Naïve or Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 *ENDURANCE-2: Study Features ENDURANCE-2 Trial Design: Randomized, double-blind, placebo-controlled
More informationHIV-HCV Co-Infection in Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School
HIV-HCV Co-Infection in 2018 Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School AASLD/IDSA and DHHS Guidance: HIV/HCV Coinfection All pts with HIV should be screened
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationHCV Disease Outcomes in the US. Hepatitis C New Medications, New Hope and New Opportunities for Primary Care. Learning Objectives 10/13/17
Hepatitis C New Medications, New Hope and New Opportunities for Primary Care Disclosures: Grant for quality improvement Gilead In this talk, 10 drugs will be discussed, 4 of which are manufactured by Gilead.
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
April 1, 2017 Bulletin #165 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Related Information for Prescribers: Only prescribers who have completed
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationMavyret (glecaprevir/pibrentasvir)
(glecaprevir/pibrentasvir) Override(s) Prior Authorization Quantity Limit Medication (glecaprevir/pibrentasvir) Approval Duration Based on Genotype, Treatment Status, or Cirrhosis Status. Quantity Limit
More informationHepatitis C. No disclosures. 1. The USPSTF recommends Hepatitis C screening in which patient populations?
Hepatitis C Jennifer Acosta PA-C No disclosures 1. The USPSTF recommends Hepatitis C screening in which patient populations? a. All adults at least once b. Immigrants to the US and those over age 65 c.
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Harvoni Page: 1 of 7 Last Review Date: June 19, 2015 Harvoni Description Harvoni (ledipasvir &
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationClinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: GA.PMN.24 Product: Medicaid Effective Date: 9/17
Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: GA.PMN.24 Product: Medicaid Effective Date: 9/17 Last Review Date: 9/17 Revision Log See Important Reminder at the end of this policy
More informationPegylated Interferon Agents for Hepatitis C
Applicable X X X X X X X Pegylated Interferon Agents for Hepatitis C Override(s) Prior Authorization Quantity Limit Initial for Monotherapy or Combination with Ribavirin based on Genotype, Status, or Co-Infection
More information